Business Description
Evaxion AS
ISIN : US29970R3030
Share Class Description:
EVAX: ADRTotal Employee Number:
46Description
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.97 | |||||
Equity-to-Asset | 0.49 | |||||
Debt-to-Equity | 0.75 | |||||
Debt-to-EBITDA | -0.72 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -8.44 | |||||
Beneish M-Score | -3.83 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 71.4 | |||||
3-Year EPS without NRI Growth Rate | 75.3 | |||||
3-Year FCF Growth Rate | 73.4 | |||||
3-Year Book Growth Rate | -50.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 22.39 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 69.25 | |||||
9-Day RSI | 66.05 | |||||
14-Day RSI | 60.74 | |||||
3-1 Month Momentum % | -27.45 | |||||
6-1 Month Momentum % | -12.17 | |||||
12-1 Month Momentum % | -7.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.06 | |||||
Quick Ratio | 5.06 | |||||
Cash Ratio | 4.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -158.5 | |||||
Shareholder Yield % | 12.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -116.04 | |||||
Net Margin % | -115.56 | |||||
EBITDA Margin % | -131.58 | |||||
FCF Margin % | -88.57 | |||||
OCF Margin % | -88.43 | |||||
ROA % | -35.02 | |||||
ROIC % | -97.78 | |||||
3-Year ROIIC % | -1374.34 | |||||
ROC (Joel Greenblatt) % | -299.79 | |||||
ROCE % | -44.44 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 1.03 | |||||
PS Ratio | 2.85 | |||||
PB Ratio | 2.94 | |||||
Price-to-Tangible-Book | 2.95 | |||||
EV-to-EBIT | -2.13 | |||||
EV-to-Forward-EBIT | -0.76 | |||||
EV-to-EBITDA | -2.13 | |||||
EV-to-Revenue | 2.81 | |||||
EV-to-Forward-Revenue | 1.55 | |||||
EV-to-FCF | -3.17 | |||||
Price-to-GF-Value | 1.01 | |||||
| Price-to-Net-Current-Asset-Value | 4.67 | |||||
| Price-to-Net-Cash | 6.72 | |||||
Earnings Yield (Greenblatt) % | -46.95 | |||||
FCF Yield % | -23.75 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EVAX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Evaxion AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.492 | ||
| EPS (TTM) ($) | -1.5 | ||
| Beta | 0.465 | ||
| 3-Year Sharpe Ratio | -0.71 | ||
| 3-Year Sortino Ratio | -0.93 | ||
| Volatility % | 86.83 | ||
| 14-Day RSI | 60.74 | ||
| 14-Day ATR ($) | 0.257129 | ||
| 20-Day SMA ($) | 3.090795 | ||
| 12-1 Month Momentum % | -7.67 | ||
| 52-Week Range ($) | 2.52 - 12.1499 | ||
| Shares Outstanding (Mil) | 8.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Evaxion AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Evaxion AS Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-19 | In 85 days | ||
| Third quarter earnings results for 2026 | 2026-11-19 | In 85 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-20 14:30 | 3.15 (+3.96%) | ||
| Second quarter earnings results for 2026 | 2026-08-20 | 3.15 (+3.96%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:30 | 4.41 (-0.90%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 4.41 (-0.90%) | ||
| General meeting for 2025 | 2026-04-16 14:00 | 4.14 (+0.24%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-06 08:30 | 3.40 (+7.26%) | ||
| Annual report for 2025 | 2026-03-05 | 3.11 (+0.65%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 3.11 (+0.65%) |
Show
Entries
Evaxion AS Frequently Asked Questions
What is Evaxion AS(EVAX)'s stock price today?
The current price of EVAX is $3.36. The 52 week high of EVAX is $12.15 and 52 week low is $2.52.
When is next earnings date of Evaxion AS(EVAX)?
The next earnings date of Evaxion AS(EVAX) is 2026-11-19.
Does Evaxion AS(EVAX) pay dividends? If so, how much?
Evaxion AS(EVAX) does not pay dividend.
Press Release
Articles on Evaxion AS
Headlines
See More- 1
Aug 20, 2026
Evaxion Biotech GAAP EPS of -$0.01 in-line
Seeking Alpha • 6:33am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers